What is semaglutide and how is it different from natural GLP-1?

Semaglutide is a synthetic molecule that mimics GLP-1, a hormone your gut releases after eating. The key difference is durability — natural GLP-1 breaks down within minutes, while semaglutide is engineered to stay active for roughly a week after injection. This longer action is what makes it useful as a once-weekly research and clinical compound.[4]

What weight loss results have clinical trials found with semaglutide?

Results vary by dose and population. In a major trial of people with obesity and type 2 diabetes, participants lost an average of 9.6% of body weight over 68 weeks.[2] In people without diabetes, a meta-analysis of four trials found an average reduction of nearly 12% from baseline body weight.[3]

What are the main side effects researchers have observed?

The most commonly reported side effects are gastrointestinal — nausea, vomiting, and diarrhoea — which are usually mild to moderate and tend to decrease over time.[1] Gallstone formation is also a noted risk. Researchers continue to monitor for rarer events involving the pancreas and thyroid, though no definitive increased risk has been established yet.[1]

Is semaglutide only being studied for weight loss?

No. While weight management and type 2 diabetes are the most-studied areas, researchers are also investigating semaglutide's effects on cardiovascular outcomes and non-alcoholic fatty liver disease (NASH).[4] Its receptors are found in the brain, heart, kidneys, and gut, suggesting a broad range of potential biological effects worth exploring.

Semaglutide: What the Research Shows

So, What Exactly Is Semaglutide?

Your gut makes a hormone called GLP-1 (glucagon-like peptide-1) every time you eat. It tells your pancreas to release insulin and signals your brain that you're full. Semaglutide is a lab-made molecule designed to mimic that hormone — but it lasts far longer in the body than the natural version.^[4]

Think of it like a slow-release version of your own appetite signal. Instead of fading within minutes the way natural GLP-1 does, semaglutide can stay active for about a week after a single injection.^[4]

How Does It Work in the Body?

GLP-1 receptors — the docking sites that semaglutide latches onto — are found all over the body: in the pancreas, the gut, the heart, the kidneys, and crucially, the brain.^[4]

Animal research has shown that semaglutide works through multiple brain pathways to reduce food intake and lower body weight.^[5] It's not just one switch being flipped — it's more like a distributed network of signals all nudging in the same direction.

It also comes in two forms: a weekly injection under the skin, and a daily pill — making it the only GLP-1 drug currently available in both formats.^[1]

What Is Research Studying It For?

Type 2 diabetes — helping control blood sugar
Obesity and weight management — reducing body weight in people with and without diabetes
Cardiovascular outcomes — whether it reduces heart attack and stroke risk
Non-alcoholic fatty liver disease (NASH) — an area of active investigation^[4]

What Does the Evidence Actually Show?

Weight Loss in People With Diabetes

The STEP 2 trial was a large, rigorous study — randomised, double-blind, placebo-controlled (the gold standard of clinical research). It enrolled over 1,200 adults who had both obesity and type 2 diabetes. After 68 weeks, those taking semaglutide 2.4 mg lost an average of 9.6% of their body weight, compared to just 3.4% in the placebo group.^[2] Nearly 69% of the semaglutide group lost at least 5% of their body weight, versus 28.5% on placebo.^[2]

Weight Loss in People Without Diabetes

A 2022 systematic review pooled data from four randomised controlled trials covering 3,613 people with obesity who did not have diabetes. The average weight reduction with semaglutide was 11.85% from baseline — a statistically significant result.^[3] That's a meaningful drop for most people.

What About Safety?

The most common side effects are gastrointestinal — nausea, vomiting, diarrhoea. These are mostly mild to moderate and tend to ease over time.^[1] The same 2022 review found that people on semaglutide were about 1.59 times more likely to experience gut-related side effects than those on placebo.^[3]

Gallstone formation (cholelithiasis) is a noted risk.^[1] Researchers are also monitoring for pancreatic and thyroid concerns, though definitive conclusions can't yet be drawn due to the low rate of these events in trials so far.^[1]

People with existing diabetic eye disease (retinopathy) need particular monitoring, especially if also using insulin.^[1]

Where Does the Research Stand Right Now?

The evidence for semaglutide's role in weight management is strong and growing. Studies in non-diabetic populations are especially compelling, with nearly 12% average weight loss across multiple trials.^[3] Research into cardiovascular benefits, liver disease, and newer formulations is ongoing.^[4]

It's worth noting that most major trials have been funded by the manufacturer (Novo Nordisk), which is standard in pharmaceutical research but worth keeping in mind when reading results.^[2]

Curious About Dosing Schedules Used in Research?

If you want to understand the dose ranges researchers have used in studies, check out the semaglutide dosage chart for a clear breakdown. You can also use our calculator to explore how research protocols are structured. Remember: this site is for educational and research reference only — always work with a qualified clinician for any health decisions.

Sources

Safety of Semaglutide. — Frontiers in endocrinology, 2021. PMID 34305810.
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. — Lancet (London, England), 2021. PMID 33667417.
Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. — Journal of the ASEAN Federation of Endocrine Societies, 2022. PMID 36578889.
The Discovery and Development of Liraglutide and Semaglutide. — Frontiers in endocrinology, 2019. PMID 31031702.
Semaglutide lowers body weight in rodents via distributed neural pathways. — JCI insight, 2020. PMID 32213703.
Wegovy (semaglutide): a new weight loss drug for chronic weight management. — Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2022. PMID 34706925.

Semaglutide Explained: What Research Actually Shows